One of the tests, InBios International’s SCoV-2 Ag Detect Rapid Self-Test, accurately diagnosed infections between 81.2 percent to 90.7 percent of the time. The other at-home test, Abbott’s BinaxNOW COVID-19 Ag Card, found similar results, according to the study published Aug. 14 in JAMA.
The research, which was conducted by researchers from the University of Washington in Seattle and the University of Nevada in Reno, also found “no significant differences” across different variants and subvariants. Together, the diagnostic specificity was 99.8 percent.
“Although more clinical studies are needed, the ongoing home-based rapid antigen testing programs may be an important intervention to reduce global SARS-CoV-2 transmission,” they wrote.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
